Showing results (151-160 of 264) with videos related to
Sort By:
Pageof 27
International Journal of Radiation Oncology, Biology, Physics|December 9, 2019
Standard and Hypofractionated Dose Escalation to Intraprostatic Tumor Nodules in Localized Prostate Cancer: Efficacy and Toxicity in the DELINEATE TrialJulia R Murray, Alison C Tree, Emma J Alexander, et al.Frontiers in Oncology|September 22, 2022
Adaptive magnetic resonance image guided radiation for intact localized prostate cancer how to optimally test a rapidly emerging technologyWilliam A Hall, Amar U Kishan, Emma Hall, et al.European Urology|January 6, 2020
The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the TestisMichael Cullen, Robert Huddart, Johnathan Joffe, et al.International Journal of Cancer|November 4, 2004
Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 yearsMartin J Slade, Anjana Singh, Brendan M Smith, et al.International Journal of Radiation Oncology, Biology, Physics|July 28, 2024
Bladder Tumor-Focused Adaptive Radiation Therapy: Clinical Outcomes of a Phase I Dose Escalation StudyShaista Hafeez, Karole Warren-Oseni, Kelly Jones, et al.The British Journal of Nutrition|January 20, 2010
Dietary fat and early-onset prostate cancer riskArtitaya Lophatananon, Jane Archer, Douglas Easton, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2008
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone drivenGerhardt Attard, Alison H M Reid, Timothy A Yap, et al.European Urology|May 16, 2022
Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 TrialEmma Hall, Syed A Hussain, Nuria Porta, et al.European Urology Oncology|May 13, 2026
Outcomes of Intermediate Risk Non-muscle-invasive Bladder Cancer Receiving Adjuvant Treatment: A Pooled Analysis of Four Randomized Controlled TrialsWei Shen Tan, Ashish M Kamat, Rebecca Lewis, et al.The Lancet. Oncology|February 3, 2007
Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled studyRobert E Coleman, Linda M Banks, Samia I Girgis, et al.Pageof 27